Medicinal Chemistry Research

, Volume 23, Issue 4, pp 1690–1700 | Cite as

Multitargeted molecular docking study of plant-derived natural products on phosphoinositide-3 kinase pathway components

  • Pushpendra Singh
  • Felix Bast
Original Research


Phosphoinositide-3 kinase (PI3K) signaling pathway comprises of a cornucopia of protein molecules capable of regulating numerous cellular events, including cell survival, cell cycle regulation, angiogenesis, and apoptosis. Deregulation of PI3K downstream signaling is a phenomenon commonly seen in various types of cancer and also held responsible for poor prognosis and resistance to chemotherapy. Targeting PI3K signaling pathway has become a new and promising strategy in combating cancer. In the present study, PI3K signaling components PI3K, PDK1, Akt, and mTOR were chosen and 51 natural compounds along with 17 reference compounds were selected as ligand with the aid of PubMed published literature search. Ligands were docked to protein molecules by using Maestro 9.3 (Schrödinger Inc.). It was discovered in this study that compounds myricetin, quercetin, morin, luteolin, and emodin yielded excellent dock score with the proteins concluded with the help of docking free energy. The remarkable feature of these compounds are their various pharmacodynamics and pharmacokinetic characteristics, many of which are in accordance with the “Lipinski’s Rule of five”. The docking study carried out is an endeavor to portray the docking of these compounds with the proteins, to summarize the various Gscore, hydrogen bond, electrostatic bond, and to chart out various factors that are decisive for and also govern the protein–ligand interactions.


Cancer Phosphoinositide-3 kinase Natural product compounds Maestro 9.3 



We would like to thank Vice Chancellor, Central University of Punjab, Bathinda, Punjab, (India) for supporting this study with infrastructural requirements. This study was also supported by a Senior Research fellowship Grant-in-aid from Indian Council of Medical Research (ICMR), Government of India awarded to PS. We also thank executive director, Schrödinger, for providing Maestro 9.3 technical support that has tremendously helped in this study. We would like to thank Dr. Pawan Kumar Gupta and Dr. Bhupesh Goyal, Assistant Professors, Centre for Computational Sciences, School of Basic and Applied Sciences, Central University of Punjab, Bathinda, Punjab, (India) for their suggestions and comments that helped tremendously to improve this article.


  1. Antonarakis ES, Carducci MA, Eisenberger MA (2010) Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 291:1–13. doi: 10.1016/j.canlet.2009.08.012 PubMedCentralCrossRefPubMedGoogle Scholar
  2. Baldo P et al (2008) mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets 8:647–665CrossRefPubMedGoogle Scholar
  3. Bartholomeusz C, Gonzalez-Angulo AM (2012) Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 16:121–130. doi: 10.1007/s11912-012-0227-y CrossRefPubMedGoogle Scholar
  4. Bolton EE et al (2008) PubChem: integrated platform of small molecules and biological activities. Annu Rep Comput Chem 4:217–241CrossRefGoogle Scholar
  5. Chen YL, Law P-Y, Loh HH (2005) Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anti-Cancer Agents 5:575–589CrossRefPubMedGoogle Scholar
  6. Cho JY, Park J (2008) Contribution of natural inhibitors to the understanding of the PI3K/PDK1/PKB pathway in the insulin-mediated intracellular signaling cascade. Int J Mol Sci 9:2217–2230. doi: 10.3390/ijms9112217 PubMedCentralCrossRefPubMedGoogle Scholar
  7. da Rocha AB, Lopes RM, Schwartsmann G (2001) Natural products in anticancer therapy. Curr Opin Pharmacol 1:364–369CrossRefPubMedGoogle Scholar
  8. Downward J (2008) Targeting RAS and PI3K in lung cancer. Nat Med 14:1315–1316. doi: 10.1038/nm1208-1315 CrossRefPubMedGoogle Scholar
  9. Drews Jr (2000) Drug discovery: a historical perspective. Science 287:1960–1964CrossRefPubMedGoogle Scholar
  10. Easton J, Houghton P (2006) mTOR and cancer therapy. Oncogene 25:6436–6446CrossRefPubMedGoogle Scholar
  11. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5:671–688CrossRefPubMedGoogle Scholar
  12. Freeman-Cook KD et al (2010) Design of selective, ATP-competitive inhibitors of Akt. J Med Chem 53:4615–4622. doi: 10.1021/jm1003842 CrossRefPubMedGoogle Scholar
  13. Friesner RA et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749CrossRefPubMedGoogle Scholar
  14. Friesner RA et al (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177–6196CrossRefPubMedGoogle Scholar
  15. Halgren TA et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750–1759CrossRefPubMedGoogle Scholar
  16. Hay N (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8:179–183CrossRefPubMedGoogle Scholar
  17. Hillman GG (2012) Dietary agents in cancer chemoprevention and treatment. J Oncol 2012. doi: 10.1155/2012/749310
  18. Huang W et al (2012) Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific Protease 1 expression. PLoS ONE 7:e37693. doi: 10.1371/journal.pone.0037693 PubMedCentralCrossRefPubMedGoogle Scholar
  19. Jorgensen WL, Duffy EM (2002) Prediction of drug solubility from structure. Adv Drug Deliver Rev 54:355–366CrossRefGoogle Scholar
  20. Jorgensen WL, Tirado-Rives J (1988) The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc 110:1657–1666CrossRefGoogle Scholar
  21. Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225–11236. doi: 10.1021/ja9621760 CrossRefGoogle Scholar
  22. Keum Y-S et al (2009) Pharmacokinetics and pharmacodynamics of broccoli sprouts on the suppression of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: implication of induction of Nrf2, HO-1 and apoptosis and the suppression of Akt-dependent kinase pathway. Pharm Res 26:2324–2331. doi: 10.1007/s11095-009-9948-5 CrossRefPubMedGoogle Scholar
  23. Kim HY et al (2012) Raf and PI3K are the molecular targets for the anti-metastatic effect of luteolin. Phytother Res. doi: 10.1002/ptr.4888 Google Scholar
  24. Kuo H-M et al (2007) Morin inhibits the growth of human leukemia HL-60 cells via cell cycle arrest and induction of apoptosis through mitochondria dependent pathway. Anticancer Res 27:395–405. doi: 10.1002/ptr.4888 PubMedGoogle Scholar
  25. Lin Y et al (2008) Luteolin, a flavonoid with potentials for cancer prevention and therapy. Curr Cancer Drug Targets 8(7):634–646PubMedCentralCrossRefPubMedGoogle Scholar
  26. Liu KC et al (2012) The roles of endoplasmic reticulum stress and mitochondrial apoptotic signaling pathway in quercetin-mediated cell death of human prostate cancer PC-3 cells. Environ Toxicol. doi: 10.1002/tox.21769 Google Scholar
  27. Lopez-Lazaro M (2009) Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem 9:31–59CrossRefPubMedGoogle Scholar
  28. LoPiccolo J et al (2008) Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11:32. doi: 10.1016/j.drup.2007.11.003 PubMedCentralCrossRefPubMedGoogle Scholar
  29. Lu JJ et al (2004) Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. J Med Chem 47:6104–6107CrossRefPubMedGoogle Scholar
  30. März AM et al (2013) Large FK506-binding proteins shape the pharmacology of rapamycin. Mol Cell Biol 33:1357–1367. doi: 10.1128/MCB.00678-12 PubMedCentralCrossRefPubMedGoogle Scholar
  31. Morales P, Haza AI (2012) Selective apoptotic effects of piceatannol and myricetin in human cancer cells. J Appl Toxicol 32:986–993. doi: 10.1002/jat.1725 CrossRefPubMedGoogle Scholar
  32. Morgan TM, Koreckij TD, Corey E (2009) Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 9(2):237–249PubMedCentralCrossRefPubMedGoogle Scholar
  33. Morgensztern D, McLeod HL (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16:797–803CrossRefPubMedGoogle Scholar
  34. Morphy R (2010) Selectively nonselective kinase inhibition: striking the right balance. J Med Chem 53:1413–1437. doi: 10.1021/jm901132v CrossRefPubMedGoogle Scholar
  35. Murphy ST et al (2011) Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1). J Med Chem 54:8490–8500. doi: 10.1021/jm201019k CrossRefPubMedGoogle Scholar
  36. Nishimura N et al (2011) Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure–activity relationships of a series of quinoline and quinoxaline derivatives. J Med Chem 54:4735–4751. doi: 10.1021/jm200386s CrossRefPubMedGoogle Scholar
  37. O’Reilly KE et al (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500–1508PubMedCentralCrossRefPubMedGoogle Scholar
  38. Phosrithong N, Ungwitayatorn J (2010) Molecular docking study on anticancer activity of plant-derived natural products. Med Chem Res 19:817–835. doi: 10.1007/s00044-009-9233-5 CrossRefGoogle Scholar
  39. Pratheeshkumar P et al (2012) Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS ONE 7:e47516. doi: 10.1371/journal.pone.0047516 PubMedCentralCrossRefPubMedGoogle Scholar
  40. Rao YK et al (2010) Identification of antrocin from Antrodia camphorata as a selective and novel class of small molecule inhibitor of Akt/mTOR signaling in metastatic breast cancer MDA-MB-231 cells. Chem Res Toxicol 24:238–245. doi: 10.1021/tx100318m CrossRefPubMedGoogle Scholar
  41. Roell D, Baniahmad A (2011) The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth Mol. Cell Endocrinol 332:1–8. doi: 10.1016/j.mce.2010.09.013 CrossRefGoogle Scholar
  42. Sarkar FH, Li Y (2006) Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 66:3347–3350CrossRefPubMedGoogle Scholar
  43. Sarker D et al (2009) Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15:4799–4805. doi: 10.1158/1078-0432.CCR-08-0125 CrossRefPubMedGoogle Scholar
  44. Shivakumar D et al (2010) Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J Chem Theory Comput 6:1509–1519. doi: 10.1021/ct900587b CrossRefGoogle Scholar
  45. Singh SV et al (2009) Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res 69:2117–2125. doi: 10.1158/0008-5472.CAN-08-3502 PubMedCentralCrossRefPubMedGoogle Scholar
  46. Sivaramakrishnan V, Devaraj SN (2010) Morin fosters apoptosis in experimental hepatocellular carcinogenesis model. Chem-Biol Interact 183:284–292. doi: 10.1016/j.cbi.2009.11.011 CrossRefPubMedGoogle Scholar
  47. Sun F et al (2012) Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer 64:599–606. doi: 10.1080/01635581.2012.665564 CrossRefPubMedGoogle Scholar
  48. Sunil H (2012) Inhibition studies of naturally occurring terpene based compounds with cyclin-dependent kinase 2 enzyme. J Comput Syst Sci doi: 10.4172/jcsb.1000092
  49. Wang P, Heber D, Henning SM (2012) Quercetin increased the antiproliferative activity of green tea polyphenol (-)-epigallocatechin gallate in prostate cancer cells. Nutr Cancer 64:580–587. doi: 10.1080/01635581.2012.661514 PubMedCentralCrossRefPubMedGoogle Scholar
  50. Watanabe R, Wei L, Huang J (2011) mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med 52:497–500. doi: 10.2967/jnumed.111.089623 PubMedGoogle Scholar
  51. Wong K–K, Engelman JA, Cantley LC (2010) Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20:87–90. doi: 10.1016/j.gde.2009.11.002 PubMedCentralCrossRefPubMedGoogle Scholar
  52. Zhang X, et al (2013) Myricetin induces apoptosis in Hepg2 cells through Akt/P70s6 k/bad signaling and mitochondrial apoptotic pathway. Anticancer Agents Med Chem. [Epub ahead of print]Google Scholar
  53. Zhang X, Jin B, Huang C (2007) The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention. Curr Cancer Drug Targets 7:305–316CrossRefPubMedGoogle Scholar
  54. Zhou H, Luo Y, Huang S (2010) Updates of mTOR inhibitors. Anticancer Agents Med Chem 10(7):571–581PubMedCentralCrossRefPubMedGoogle Scholar
  55. Zhou S, Li Y, Hou T (2013) Feasibility of using molecular docking-based virtual screening for searching dual target kinase inhibitors. J Chem Inf Model. doi: 10.1021/ci400065e PubMedCentralGoogle Scholar
  56. Zhu Q et al (2011) Quercetin induces the apoptosis of human PC-3 cells. Natl J Androl 17(9):790–793Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Centre for Biosciences, School of Basic and Applied ScienceCentral University of PunjabBathindaIndia

Personalised recommendations